# Diabetes Research Hub — Monitor Report

**Run date:** 2026-07-11 (automated scheduled run)
**Scan window:** since 2026-07-10 monitor run
**Prepared by:** automated hub monitor

---

## TL;DR (what's actionable)

1. **One genuinely new external item this week:** Kailera/Hengrui oral GLP-1 RA **HRS-7535/KAI-7535** reported positive Phase 3 topline (HARBOR-1 obesity + OUTSTAND-2 T2D, both China) on **2026-07-07**. Not in our tracked ClinicalTrials.gov or PubMed data yet. *[Likely] worth adding to trial intelligence.*
2. **Data pipeline is healthy and fresh** — trials + PubMed snapshots both regenerated 2026-07-11 02:05. Gap analysis is 1 day old.
3. **Low-signal week internally:** 3 new trials (all minor/device or completed-with-results), 0 status changes, 0 new results posted, 19 new PubMed papers (1 cross-domain).
4. **Data-quality flag:** the `GLP-1 Pharmacogenomics` PubMed domain returned **0 papers** this run — likely a query/terminology issue, not a real signal. Recommend a spot-check.

---

## File System Status

All five key outputs are present and current:

| File | Last modified | Status |
|------|---------------|--------|
| hub_monitor_report.md | 2026-07-11 02:19 | Fresh |
| clinical_trials_latest.json | 2026-07-11 02:05 | Fresh (855 trials) |
| pubmed_recent_latest.json | 2026-07-11 02:05 | Fresh (157 papers) |
| literature_gap_data.json | 2026-07-10 02:17 | 1 day old |
| literature_gap_report.md | 2026-07-10 03:09 | 1 day old |

Snapshot chains are intact and daily through 2026-07-11 for both clinical trials and PubMed.

**Staleness note:** hub_monitor flags **807 result files older than 14 days** and reports 807/1033 tracked files unchanged. Most are archival snapshots and dashboards; not action-worthy on their own, but the gap-evidence and citation-validation artifacts (last touched 2026-07-10) should be regenerated if any gap classifications are promoted past BRONZE.

---

## Clinical Trial Changes

**Snapshot diff (2026-07-10 → 2026-07-11):** 3 new trials, 0 removed, **0 status changes, 0 new results posted.**

The 3 new trials are low priority:

- **NCT07696273** (RECRUITING, device) — Indiana University, miniaturized breath-based sensor for hypo-/hyperglycemia detection.
- **NCT07696988** (NOT_YET_RECRUITING, device) — VA, peripheral nerve stimulation for vascular/limb health.
- **NCT04717050** (COMPLETED w/ results, NA phase) — Dana-Farber, physical activity in obese Latina breast-cancer survivors (metabolic dysregulation).

**Trial landscape (855 total):** 318 completed w/ results, 265 recruiting, 155 not-yet-recruiting, 110 active-not-recruiting.

**Key Phase 3 recruiting trials from tracked organizations (unchanged, still open):**

- **Vertex** — VX-880 (zimislecel) T1D islet cell therapy: NCT04786262 (Phase 3, RECRUITING) and NCT06832410 (Phase 3, RECRUITING, kidney-transplant cohort). VX-264 (encapsulated) NCT-Phase 1/2 active-not-recruiting.
- **Eli Lilly** — Baricitinib in T1D: NCT07222137 (delay Stage 3) and NCT07222332 (BARICADE-PRESERVE, newly diagnosed), both Phase 3 RECRUITING. Retatrutide/orforglipron/tirzepatide Phase 3 programs largely **active-not-recruiting** (readouts flowing).
- **Novo Nordisk** — Insulin icodec T1D (NCT07076199, Phase 3 RECRUITING); CagriSema NCT07564414 (Phase 3 RECRUITING). Multiple CagriSema/icodec Phase 3s active-not-recruiting.
- **Sanofi** — Teplizumab NCT07088068 (Phase 3 RECRUITING) in ages 1–25 with Stage 3 T1D.

No zimislecel-specific PubMed publications appeared this run (0 therapy hits) despite active Vertex Phase 3 recruitment — the literature still trails the trial pipeline here.

---

## PubMed Highlights

**Volume trend:** 152 (07-04) → 152 (07-07) → 155 (07-10) → **157 (07-11)**. Diff vs. yesterday: **19 new, 17 dropped** from the 30-day rolling window. Slow, steady turnover — no surge.

**Cross-domain papers (10 total; highest-value):**

- **[42429765]** *(NEW this run, only new cross-domain paper)* — "Adaptive graph learning of microbial phylogeny…microbiome-based host phenotype prediction." Spans **AI/ML + Biomarker + Microbiome** (triple-domain). *[Likely] relevant to Tier 1 Multi-Omics work — worth a read.*
- **[42419792]** — Network meta-analysis of anti-obesity drugs, spanning **orforglipron + retatrutide + CagriSema** (three tracked therapies in one paper).
- **[42387220]** — CRISPR hypoimmunogenic engineering of MSC-derived insulin-producing cells (Stem Cell Cure + Gene Therapy).
- **[42420766]** — Early worsening of diabetic retinopathy after starting closed-loop/AID systems (Closed Loop + Complications) — clinically notable safety-signal review.
- **[42332392]** — Teplizumab (Tzield) for delay of T1D (Immunotherapy + tracked therapy).

**Key therapy mentions this run:** orforglipron 9, retatrutide 6, CagriSema 4, teplizumab 4, icodec 4, baricitinib 2, dapagliflozin 50 (paper-level: ~5); **zimislecel 0.**

**Domain activity:** 12 of 16 domains at the 10-paper query cap (healthy). Low: Epigenetics (5), LADA (7), Drug Repurpose (8). **`GLP-1 Pharmacogenomics` = 0 — anomalous; flag for query check.**

---

## Gap Analysis Summary (BRONZE — expert confirmation pending)

Top 5 under-researched intersections (Gap Score 100, i.e. ~0 joint publications where individual-domain volume predicts more):

1. **Beta Cell Regen × Health Equity** (0 joint) — who gets access to regenerative therapies is unstudied.
2. **Insulin Resistance × Islet Transplant** (1 joint) — IR in graft recipients affects survival; barely studied.
3. **Islet Transplant × Drug Repurposing** (0 joint) — repurposing immunosuppressants for islet protection; no computational screen exists.
4. **Islet Transplant × Health Equity** (0 joint) — access-equity research absent for a select-center therapy.
5. **Gene Therapy × LADA** (0 joint) — LADA's autoimmune mechanism is a gene-therapy candidate; no crossover.

**Alignment with our Tier 1 contribution areas:** several top gaps sit squarely in Tier 1 lanes and are the best candidates to actually work:

- **Drug Repurposing (Tier 1 #4):** gaps #3 (Islet Transplant × Drug Repurposing), #8 (Glucokinase × Drug Repurposing), #12 (Drug Repurposing × Health Equity), #13 (Drug Repurposing × LADA).
- **Multi-Omics Biomarker Integration (Tier 1 #1):** unclassified gaps Multi-Omics × LADA and Metabolomics × LADA — computationally tractable with public summary stats.

These are the intersections where we have data access + method + a real gap, per the Doctrine.

---

## Breaking News (web, last 7 days)

**NEW this week — not in yesterday's report or our tracked data:**

- **Kailera Therapeutics / Hengrui — oral GLP-1 RA HRS-7535 (KAI-7535):** positive Phase 3 topline announced **2026-07-07** — HARBOR-1 (obesity, China) and OUTSTAND-2 (T2D, China). **Evidence level: Phase 3 RCT topline (Level 1b, press release — full data pending).** *Action candidate for trial intelligence.*
- **AstraZeneca — elecoglipron (oral small-molecule GLP-1 RA):** advanced to **Phase III** program (cardiometabolic/kidney portfolio). Development-stage news, not results.

**Already reflected in tracked data (no new action):**

- Teplizumab (Tzield) pediatric label expansion — FDA action mid-2026; already in PubMed [42332392, 42295172]. *Note: confirm exact scope — current search surfaced an ages 8–17 Stage-3 indication; yesterday's report cited ≥1 yr Stage 2. Worth reconciling against the FDA notice.*
- Orforglipron, retatrutide TRANSCEND/TRIUMPH — earlier-2026 readouts, already tracked.
- Generic dapagliflozin (FDA 2026-04-07) — old.

No genuinely new **FDA approval** in the last 7 days.

---

## Recommended Actions

1. **Add Kailera/Hengrui HRS-7535 (KAI-7535) to trial intelligence** — search ClinicalTrials.gov for the HARBOR-1 / OUTSTAND-2 NCT IDs; if present, confirm they're captured next `baseline_clinical_trials.py` run. New Phase 3 oral GLP-1 competitor worth tracking.
2. **Spot-check the `GLP-1 Pharmacogenomics` PubMed query** — 0 returns is almost certainly a terminology/query artifact. Verify the search string in `baseline_pubmed_alerts.py`.
3. **Read cross-domain paper [42429765]** (microbiome × AI/ML × biomarker) — aligns with Tier 1 Multi-Omics; candidate for the paper library / synthesis queue.
4. **Reconcile the teplizumab pediatric-indication scope** (ages 8–17 Stage 3 vs. ≥1 yr Stage 2) against the primary FDA notice before it propagates into any tracked claim — Doctrine requires source-of-record for regulatory claims.
5. **Prioritize a Drug-Repurposing gap deep-dive** — gaps #3/#8/#12/#13 all fall in Tier 1 #4 and share a method (network pharmacology on DrugBank/OpenTargets). Highest-leverage next computational project.
6. **No refresh needed for trials/PubMed** (regenerated today). Consider re-running `project1_literature_gap_analysis.py` if any gap is promoted past BRONZE, since gap-evidence artifacts are 1 day old.

---

*All new external claims labeled with evidence level per Research Doctrine. This was a review-only run; no existing files were modified. Gap classifications remain BRONZE pending expert validation.*
